Inactive Instrument

BELM PHAR Share Price Nasdaq

Equities

Biotechnology & Medical Research

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2021 62L 52Cr Sales 2022 15L 13Cr Capitalization 8L 6.86Cr
Net income 2021 -90L -75Cr Net income 2022 -2.5Cr -208.68Cr EV / Sales 2021 * -
Net cash position 2021 * - 0 Net cash position 2022 * - 0 EV / Sales 2022 * -
P/E ratio 2021 *
-
P/E ratio 2022 *
-
Employees -
Yield 2021 *
-
Yield 2022 *
-
Free-Float 98.45%
More Fundamentals * Assessed data
Dynamic Chart
Bellicum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. Its Chemical Induction of Dimerization (CID), technology platform is designed to enable control of components of the immune system in real time. CID consists of molecular switches, modified forms of these signaling proteins, which are triggered inside the patient by infusion of a small molecule, instead of by natural upstream signals. It has developed two such switches: an activation switch, designed to stimulate activation, proliferation and persistence of the immunotherapy cells and provide other immunomodulatory benefits, and a safety switch, designed to initiate programmed cell death, or apoptosis, of the immunotherapy cell.
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW